Testing effectiveness (Phase 2)Study completedNCT02252146
What this trial is testing
Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Who this might be right for
Diffuse Large B Cell Lymphoma
Idera Pharmaceuticals, Inc. 6